Lambré Claude, Barat Baviera José Manuel, Bolognesi Claudia, Cocconcelli Pier Sandro, Crebelli Riccardo, Gott David Michael, Grob Konrad, Lampi Evgenia, Mengelers Marcel, Mortensen Alicja, Rivière Gilles, Steffensen Inger-Lise, Tlustos Christina, Van Loveren Henk, Vernis Laurence, Zorn Holger, Andryszkiewicz Magdalena, di Piazza Giulio, Kovalkovicova Natalia, Liu Yi, Chesson Andrew
EFSA J. 2022 Jul 6;20(7):e07381. doi: 10.2903/j.efsa.2022.7381. eCollection 2022 Jul.
The food enzyme phospholipase A1 (phosphatidylcholine 1-acylhydrolase; EC 3.1.1.32) is produced with the genetically modified strain NZYM-LJ by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and its DNA. The food enzyme is intended to be used in baking processes. Dietary exposure to the food enzyme-total organic solids (TOS) was estimated to be up to 0.09 mg TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 957.3 mg TOS/kg bw per day, the highest dose tested, which when compared with the estimated dietary exposure, results in a margin of exposure of at least 10,600. A search for similarity of the amino acid sequence of the food enzyme to known allergens was made and one match was found. The Panel considered that, under the intended conditions of use the risk of allergic sensitisation and elicitation reactions by dietary exposure cannot be excluded, but the likelihood for this to occur is considered to be low. Based on the data provided, the Panel concludes that this food enzyme does not give rise to safety concerns under the intended conditions of use.
食品酶磷脂酶A1(磷脂酰胆碱1-酰基水解酶;EC 3.1.1.32)由诺维信公司(Novozymes A/S)使用转基因菌株NZYM-LJ生产。基因改造不存在安全问题。该食品酶不含生产生物体的活细胞及其DNA。该食品酶拟用于烘焙过程。据估计,欧洲人群通过饮食接触该食品酶的总有机固体(TOS)量高达每天0.09毫克TOS/千克体重(bw)。遗传毒性试验未表明存在安全问题。通过对大鼠进行为期90天的重复剂量口服毒性研究评估了全身毒性。专家小组确定未观察到有害作用水平为每天957.3毫克TOS/千克bw,这是测试的最高剂量,与估计的饮食接触量相比,得出的接触范围至少为10,600。对该食品酶的氨基酸序列与已知过敏原进行了相似性搜索,发现了一个匹配项。专家小组认为,在预期的使用条件下,不能排除饮食接触引起过敏致敏和激发反应的风险,但认为发生这种情况的可能性较低。根据提供的数据,专家小组得出结论,在预期的使用条件下,这种食品酶不存在安全问题。